Result: Another interesting observation is that mutations Y188C and G190A are predicted to render HIV more sensitive to Etravirine according to our model.
Figure: In particular the specific profiles of V106I, Y181C and G190A are reproduced well.
Human APOBEC3G-mediated hypermutation is associated with antiretroviral therapy failure in HIV-1 subtype C-infected individuals.
PMID: 23443042
2013
Journal of the International AIDS Society
Table: G190A
Transmission patterns of HIV-subtypes A/AE versus B: inferring risk-behavior trends and treatment-efficacy limitations from viral genotypic data obtained prior to and during antiretroviral therapy.
Result: Twenty-three, including 21 for whom these drugs where part of their first-line therapy, had at least one major NNRTI mutation, with K103N and G190A/S being the most prevalent (Table 5).
Table: G190A/S
Discussion: An example is the discrepancy between our failure to find the mutation G190AS among drug-naive individuals, in both subtypes, and the transmission of this mutation to subtype-B infected individuals reported elsewhere.
Discussion: By contrast, individuals failing EFV treatment had NNRTI-related mutations independently of subtype, in particular K103N and G190AS.
Discussion: While K103N found its way to this
Prevalence of HIV-1 drug resistance among women screening for HIV prevention trials in KwaZulu-Natal, South Africa (MTN-009).
Result: There were also multiple occurrences of Figure: Histogram showing number of women with drug resistant HIV infection that had each of the following protease inhibitor (PI), nucleoside reverse transcriptase inhibitor (NRTI) or non-nucleoside reverse transcriptase inhibitor (NNRTI) mutations M46L, I85V, K65R, L74I, K219E, M184V, K101E, V106M, Y181C or G190A.
Prevalence of etravirine (ETR)-RAMs at NNRTI failure and predictors of resistance to ETR in a large Italian resistance database (ARCA).
PMID: 23621421
2013
Clinical microbiology and infection
Abstract: V179I, Y181C and G190A were the most frequent mutations in both groups.
Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes.
PMID: 23629015
2013
The Journal of antimicrobial chemotherapy
Abstract: For etravirine, only G190A was more prevalent in B than non-B subtypes, whereas V90I and V179E were more frequent in non-B than B subtypes.
Simultaneous and sensitive detection of human immunodeficiency virus type 1 (HIV) drug resistant genotypes by multiplex oligonucleotide ligation assay.
PMID: 23660583
2013
Journal of virological methods
Abstract: Known proportions of mutant and wild-type plasmids were used to optimize a multiplex OLA for detection of K103N, Y181C, K65R, and M184V in HIV subtypes B and C, and V106M and G190A in subtype C.
Method: Amplicons from plasmid controls and specimens were tested in duplicate by SPX- and MPX-OLA using validated HIV subtype B- and subtype C-specific probes for detection of drug-resistance mutations K65R, M184V, K103N, V106M, Y181C, and G190A.
Method: OLA probes used detected mutations associated with high-level drug-resistance in HIV PMID: 23717585
2013
PloS one
Table: G190A
Evaluation of WHO immunologic criteria for treatment failure: implications for detection of virologic failure, evolution of drug resistance and choice of second-line therapy in India.
PMID: 23735817
2013
Journal of the International AIDS Society
Method: Non-nucleoside reverse transcriptase
Result: Seven (24.1%) had K103N, seven (24.1%) had G190A and six (20.7%) had K101E.
Result: There were a few NNRTI mutations present: two patients had Y181C, two had K103N, five had G190A and one had K101E.
Result: When the evolution of NNRTI mutations was assessed, three more participants developed K103N, two more developed Y181C, and six more each developed G190A and K101E.
Table: G190A
Mutation covariation of HIV-1 CRF07_BC reverse transcriptase during antiretroviral therapy.
PMID: 23788482
2013
The Journal of antimicrobial chemotherapy
Abstract: Twelve significant covariation pairs were found between five treatment-associated mutations (K103N, M184V, Q197K, G190A and Y181C) and nine overlapping polymorphisms (A36E, D39N, Y121H, D123E, R135I, T200A, R277K, L283I and D291E).